Fixed combination of amlodipine and lisinopril effectiveness in hypertensive smokers
| Autor: | Ostroumova O.D., Kochetkov A.I. |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2018 |
| Předmět: | |
| Zdroj: | Системные гипертензии, Vol 15, Iss 1, Pp 23-31 (2018) |
| Druh dokumentu: | article |
| ISSN: | 2075-082X 2542-2189 |
| DOI: | 10.26442/2075-082X_15.1.23-31 |
| Popis: | Objective. To conduct a comparative analysis of blood pressure (BP) profile characteristics in middle-aged (45–65 years) patients with stage 1–2 hypertension not associated with comorbid cardiovascular disease depending on smoking status; to estimate the influence of fixed combination of amlodipine and lisinopril (FC A/L) use on these characteristics. Materials and methods. At the first stage of the study 60 untreated patients (31 men, 29 women, mean age 53.6±0.8 years) with stage 1–2 hypertension were divided in two groups according to smoking status. The smoking group included 11 men and 11 women with mean age 53.4±1.2 years, non-smoking group – 20 men and 18 women with mean age 53.7±1.0 years. Ambulatory blood pressure monitoring (ABPM) (monitor MDP-НС-02с, DMS) and BP measurement based on Korotkov sound technique as well as transthoracic echocardiography were performed in all patients. At the second stage a subgroup of 30 untreated patients (16 men, mean age 52.7±1.11 years, 40% smokers [12 patients]) was formed. Patients received FC A/L (Ekvator®) with starting dose 5 mg/10 mg titrated every 14 days until target BP lower than 140/90 mm Hg was reached. The therapy was continued for 12 weeks, after that ABPM was performed again. Results. In smokers and non-smokers with hypertension no significant differences in BP levels in office BP measurement and ABPM were observed. At the second stage all 30 patients receiving FC A/L reached target office BP levels. In subgroups of smokers and non-smokers with hypertension significant office systolic BP (p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|